5L
MRNA icon

55I LLC’s Moderna MRNA Stock Holding History

55I LLC’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$436K Buy
+3,689
New +$560K 0.01% 412

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

55I LLC's MRNA Position: Q3 2022 in Review

55I LLC opened a new position in Moderna (MRNA) in Q3 2022: 3,689 shares worth $436K. The stake represents 0.01% of the portfolio and ranks #412 among its holdings.

915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

  • 55I LLC held 3,689 shares of Moderna worth $436K as of Q3 2022.
  • Moderna was a new 55I LLC position in Q3 2022.
  • Moderna made up 0.01% of 55I LLC's portfolio in Q3 2022, its #412 holding.
  • 915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on 55I LLC's 13F filing for Q3 2022, filed 14 Nov 2022.